Mizuho Raises Price Target of Revance Therapeutics to $33.00 in 2023.

Trending News 🌥️

Mizuho has recently increased the price target of Revance Therapeutics ($NASDAQ:RVNC) for 2023 to $33.00. This is the first time the company has set a new price target for the company. Revance Therapeutics is a biotechnology company focused on developing and commercializing innovative treatments in aesthetic and therapeutic areas. Revance Therapeutics has experienced considerable success since its inception. It has developed a number of innovative products and established its presence in the aesthetics and therapeutic spaces. The company’s products have been approved by the US Food and Drug Administration (FDA) for use in a number of indications, including glabellar lines, blepharospasm, and cervical dystonia.

This kind of success has enabled the company to receive recognition from Mizuho, which has increased its price target to $33.00. The new price target is an acknowledgment of the company’s potential to continue to show strong growth and make an impact in the aesthetic and therapeutic spaces. With its cutting-edge products, Revance Therapeutics is poised to continue to take advantage of the growing demand for innovative treatments. Its products are expected to drive more sales and help the company reach its goals in 2023. This is great news for shareholders as it will help them generate returns on their investments.

Price History

Mizuho, a financial services company, has recently raised its price target of Revance Therapeutics to $33.00 by the year 2023, citing mostly positive news coverage of the company’s progress. On Friday, REVANCE THERAPEUTICS stock opened at $31.2 and closed at $32.1, a 3.1% increase from its previous closing price of $31.2. Investors appear to be optimistic about the company’s future prospects, pushing the share price up from its opening value. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Revance Therapeutics. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Revance Therapeutics. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Revance Therapeutics. More…

Key Ratios Snapshot

Some of the financial key ratios for Revance Therapeutics are shown below. More…

Analysis

At GoodWhale, we analyze REVANCE THERAPEUTICS‘s financials to determine the company’s prospects. Our analysis using our Star Chart system classifies REVANCE THERAPEUTICS as a ‘cheetah’ – a type of company that achieved high revenue or earnings growth but is considered less stable due to lower profitability. Considering REVANCE THERAPEUTICS’s strengths and weaknesses, investors who are interested in high growth companies and are willing to take on some risk may be interested in REVANCE THERAPEUTICS. The company is strong in growth, medium in asset and weak in dividend, profitability. Although REVANCE THERAPEUTICS has strong growth prospects, the company has a low health score of 2/10 considering its cashflows and debt, which means that the company is less likely to sustain future operations in times of crisis. Therefore, investors should take this into account before investing in REVANCE THERAPEUTICS. More…

Peers

In the realm of aesthetic treatments, there is fierce competition among companies to develop the most innovative and effective products. Among these companies is Revance Therapeutics Inc, which is up against tough competition from Viva Biotech Holdings, Pharmaron Beijing Co Ltd, and CStone Pharmaceuticals. All of these companies are vying to create the best products and treatments that will appeal to consumers.

– Viva Biotech Holdings ($SEHK:01873)

Viva Biotech Holdings is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of various diseases. The company’s lead product candidate is VB-111, a first-in-class, targeted anti-cancer agent that is in Phase III clinical development for the treatment of glioblastoma, the most common and aggressive form of brain cancer. Viva Biotech has a market cap of 2.28B as of 2022 and a Return on Equity of 5.39%.

– Pharmaron Beijing Co Ltd ($SZSE:300759)

Pharmaron Beijing Co., Ltd. is a global, research-based drug discovery and development company that partners with life science organizations to transform the way therapeutics are discovered and developed. The company’s services include target identification and validation, lead optimization, preclinical and clinical research, and commercialization. Pharmaron Beijing Co., Ltd. is headquartered in Beijing, China.

– CStone Pharmaceuticals ($OTCPK:CSPHF)

CStone Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative immuno-oncology therapeutics. The company’s market cap is 508.8M as of 2022 and its ROE is -87.18%. CStone Pharmaceuticals is focused on developing and commercializing immuno-oncology therapies that target the tumor microenvironment and modulate the immune system to fight cancer. The company’s lead product candidate, CS1001, is a PD-L1/TGF-β inhibitor that is being evaluated in a global Phase III clinical trial in first-line non-small cell lung cancer.

Summary

Revance Therapeutics is a biotechnology company that develops neuromodulators for improving the appearance of wrinkles. Recently, Mizuho has raised its price target for the stock to $33.00 in 2023 due to the positive news coverage and investors responding positively to the news as the stock price saw an increase. Analyzing the stock, investors should look at the company’s financials and research & development capabilities, as well as any potential catalysts on the horizon that could drive the stock price higher.

Furthermore, with a strong balance sheet and no debt, Revance Therapeutics should be able to fund their operations and R&D programs with cash. In conclusion, Revance Therapeutics appears to be a good investment option with a potential upside in the long term.